1
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


2
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


3
Naomi Burke Anker, Jeannie M Arruda, Brian Thomas Campbell, Benito Munoz, Petpiboon Prasit, Brian A Stearns, Tao Hu: ]pyridazine compounds, -pyrrolo[3,4-, Treatment of neuropathic pain with 6. Merck & Co, Sylvia A Ayler, William Krovatin, December 16, 2008: US07465730

6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in ...


4
Jeannie M Arruda, Benito Munoz, Brian A Stearns: Prodrugs of diaryl-2-(5H)-furanone cyclooxygenase-2 inhibitors. Merck & Co, Curtis C Panzer, Valerie J Camara, March 30, 2010: US07687541

The invention encompasses the novel compounds of Formula (I) and Formula (II), which are prodrugs that convert in vivo to diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. These prodrugs are far more soluble in aqueous media than the active agents into which they ...


5
Jeannie M Arruda, Benito Munoz, Brian A Stearns: Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors. Merck And Co, May 31, 2007: US20070123587-A1

The invention encompasses the novel compounds of Formula (I) and Formula (II), which are prodrugs that convert in vivo to diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. These prodrugs are far more soluble in aqueous media than the active agents into which they ...


6
Naomi Burke Anker, Jeannie M Arruda, Brian Thomas Campbell, Benito Munoz, Petpiboon Prasit, Brian A Stearns, Tao Hu: Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds. Merck And Co, July 13, 2006: US20060154929-A1

6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in ...



Click the thumbnails below to visualize the patent trend.